Videos / Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Dr Bronwyn Jenkins

Optimising Management of Acute Migraine

A/Prof Piyush Srivastava

Heart Failure in General Practice

Dr Rashi Kalra

Carrier Screening & Medicare Rebate

Prof Adrian Esterman

The Current COVID Wave

Dr John Brannan

Triple Therapy for Severe Asthma – More Than the Sum of its Parts

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

28 November 2023

expert

Dr Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Product Explainer

Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD